Autonomix Medical (AMIX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
4 Sep, 2026Executive summary
Annual Meeting scheduled for October 29, 2026, with in-person attendance encouraged and electronic proxy voting available.
Shareholders of record as of September 8, 2026, are eligible to vote on key proposals.
Proxy materials, including the Annual Report and amendments, are accessible online to reduce environmental impact and costs.
Voting matters and shareholder proposals
Election of five directors to serve until the 2027 annual meeting.
Ratification of Forvis Mazars, LLP as independent auditor for fiscal year ending March 31, 2027.
Approval of an amendment authorizing the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25 within one year.
Approval of an amendment to the 2023 Equity Incentive Plan to increase authorized shares for issuance.
Board of directors and corporate governance
Board consists of five members, with a majority deemed independent under Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent members.
Board and committees held a total of 13 meetings in fiscal 2026, with high attendance.
Policies in place include anti-hedging, code of ethics, and insider trading policy.
Latest events from Autonomix Medical
- Registering 1,071,826 shares for resale via warrants, with proceeds for working capital if exercised.AMIX
Registration filing - Precision-guided nerve ablation technology shows strong clinical results and targets a $100B market.AMIX
Investor presentation - Net loss narrowed, cash runway shortens, and new capital raised via warrant inducement amid going concern risks.AMIX
Q1 2027 - Registering 857,462 shares for resale via warrants, with proceeds for working capital and high dilution risk.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with high risk and significant capital needs.AMIX
Registration filing - Medical device firm targets $200M shelf and $2.1M ATM amid high risk and going concern warning.AMIX
Registration filing - Offering up to 698,812 units to fund clinical trials, with no revenue and high ongoing losses.AMIX
Registration filing - Development-stage device firm registers 1.57M shares for resale; future hinges on warrant exercise and capital.AMIX
Registration filing - Flexible registration enables ongoing offerings of various securities, including a $2.1M ATM program.AMIX
Registration filing